Brought to you by the International Journal of Pharmaceutical Compounding FREE TRIAL    FORMULATIONS    MY ACCOUNT 
Compounding This Week Newsletter from www.CompoundingToday.com
Our Compounding Knowledge, Your Peace of Mind
May 19, 2017  |  Volume 14  |  Issue 20
IN THIS ISSUE
 
SUBSCRIPTIONS / INFO
 
CLASSIFIEDS
 
ABOUT COMPOUNDINGTODAY
 
FREE RESOURCES
 
SUBSCRIBER RESOURCES
IJPC's USP <800> Article Series Saves You Money!
PCCA International Seminar 2017 - Oct 4-7, Houston, Texas
 

ANNOUNCEMENT
A revised White Paper: Human-use Sterilizing Filter Issue has been posted and is available for downloading.

 
Loyd V. Allen, Jr., Ph.d., R.Ph Letter from the Editor
Pharmacogenomics and Compounding Pharmacists, Part X

Steps to Implementing Pharmacogenomics (PGx) in Your Practice

Warfarin, CYP2C9 and VKORC1

VL is a 62 yo Caucasian female who is now starting anticoagulation with warfarin for onset of atrial fibrillation. She is a Type 2 diabetic with hypertension and hyperlipidemia and is taking:

  • Metformin 500 mg BID with meals
  • Lisinopril 10 mg daily
  • Atorvastatin 20 mg daily

VL does not smoke or drink and is advised to start a heart-healthy diet including increased salad intake. Her baseline INR is 1.0 with a goal of 2.5. Her genotype profile is:

  • CYP2C9*3/*3
  • VKORC1-1639A/A

Warfarin has a narrow therapeutic window with a significant risk of bleeding; PGx testing can be used to affect medication dosing. The CYP2C9 and VKORC1 polymorphisms can affect warfarin dosing. However, not all patients with polymorphisms in CYP2C9 or VKORC1 will have a serious bleeding event; those without any polymorphism may still be susceptible to having a bleeding event due to clinical, nongenetic factors.

The CYP2C9 alleles affect the metabolism of warfarin.

The VKORC1 1173 C>T or VKORC1-1639 G>A alleles affect the formation of vitamin K-dependent clotting factors.

Dosing Considerations:

  • Patients with CYP2C9*2 or CYP2C9*3 alleles may have decreased CYP2C9 activities by 50% to 90%, requiring lower warfarin doses.
  • Haplotype A from VKORC1 SNPs is associated with lower warfarin dose requirements; VKORC1A/A genotype generally requires a lower weekly warfarin dose of 32%.
  • Haplotype B is associated with higher warfarin dose requirements; Haplotype B/B generally requires an increased weekly warfarin dose of 35%.
  • It appears from numerous reports that the VKORC1 allele is of greater importance in determining the warfarin maintenance dose than is the CYP2C9 genotype.

Dosing data from a published table extracted and presented below may be of assistance:

VKORC1 GenotypeCytochrome P450 CYP2C9 Genotypes *3/*3
A/A0.5 to 2 mg/d

Next week, we will look at some resources available to support your PGx practice.


Loyd V. Allen, Jr., PhD, RPh
Editor-in-Chief
International Journal of Pharmaceutical Compounding
Remington: The Science and Practice of Pharmacy Twenty-second edition

 

IJPC Now on Facebook and Youtube

Become a fan of the IJPC Facebook page and share ideas, photos, and keep up to date with the latest compounding information - http://www.facebook.com/IJPCompounding

Learn about the Journal's new multi-media features and view our growing collection of educational and training videos at www.ijpc.com/video or by subscribing to our Youtube channel at https://www.youtube.com/user/IJPCompounding.

 

Did You Know ...

�that "you never really know the measure of a man until there's adversity or money on the table"?

 

Tip of the Week

It is only when pretense, hypocrisy, and self-serving agendas are set aside can we approach life with understanding and compassion. Also, the more confident we feel in being who we genuinely are, the less likely we are to feel threatened by others; aggression is fed by insecurity. (Cowboy Values)

 

Looking Back

Aid the blade!
     Burma Shave

Copyright 2017
International Journal of Pharmaceutical Compounding, Inc.
122 N Bryant Ave, Edmond OK 73034
Manage my Email:
Subscribe / Un-Subscribe
Comments or Questions:
info@compoundingtoday.com
Reprints & Permissions: Reprints@ijpc.com